87 search results for: expert insights

expert video

How often do you suggest to assess sense of smell?

5 min

Rhinology

Prof. Mullol highlights the utility of visual analog scale for quick assessment of sense of smell in patients with CRSwNP.

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights the association between epidermal barrier dysfunction and S. aureus colonization in her talk at the ISDS 2023 ADVENT symposium.

expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.

expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

8 min

Pulmonology

Watch Prof G. Walter Canonica discuss the need to move beyond disease control to clinical remission in asthma and CRSwNP.

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

1 min

Dermatology

Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.

expert video

UCARE 2023: Neuronal Involvement in CSU

7 min

Dermatology

Dr. Kim provides a deep dive into the neuroimmune axis in CSU.

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

5 min

Dermatology

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

expert video

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

10 min

Pulmonology

In this ADVENT symposium at the 2024 European Respiratory Society conference, Drs. Sharon Dell and Leonard Bacharier discuss the potential domains of on therapy clinical remission in pediatric severe asthma, emphasizing lung function as a key parameter for children.

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Hong KongChange country/region